Proresolution therapy for the treatment of delayed healing of diabetic wounds

Diabetes

Volumn 62, Issue 2, 2013, Pages 618-627

  Tang, Yunan ^a   Zhang, Michael J ^a   Hellmann, Jason ^a   Kosuri, Madhavi ^a   Bhatnagar, Aruni ^a   Spite, Matthew ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RESOLVIN D1; UNCLASSIFIED DRUG; WORTMANNIN; WOUND HEALING PROMOTING AGENT; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC WOUND; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PERITONITIS; PHAGOCYTOSIS; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; WOUND; WOUND CLOSURE; WOUND HEALING IMPAIRMENT;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, TYPE 2; DOCOSAHEXAENOIC ACIDS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; PERITONITIS; PHAGOCYTOSIS; RECEPTORS, FC; THYMOCYTES; WOUND HEALING;

EID: 84873050854     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0684     Document Type: Article

References (37)

1. CDC Fact Sheet: National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States. Atlanta, GA, Centers for Disease Control and Prevention, 2011
2. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-2222
3. Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci 2011;1243:54-68
4. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008;8:923-934
5. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011;11:738-749
6. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003;361:1545-1551
7. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8: 349-361
8. Nathan C, Ding A. Nonresolving inflammation. Cell 2010;140:871-882
9. Serhan CN, Brain SD, Buckley CD, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007;21:325-332
10. Zhang MJ, Spite M. Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids. Annu Rev Nutr 2012;32:203-227
11. Chiang N, Fredman G, Bäckhed F, et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 2012;484:524-528
12. Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009;461:1287-1291
13. Ravichandran KS. Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity 2011;35:445-455
14. Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 2006;129:1673-1682
15. Hellmann J, Tang Y, Kosuri M, Bhatnagar A, Spite M. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J 2011;25:2399-2407
16. González-Périz A, Horrillo R, Ferré N, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009;23:1946-1957
17. Galiano RD, Michaels J 5th, Dobryansky M, Levine JP, Gurtner GC. Quantitative and reproducible murine model of excisional wound healing. Wound Repair Regen 2004;12:485-492
18. Yang R, Chiang N, Oh SF, Serhan CN. Metabolomics-lipidomics of eico-sanoids and docosanoids generated by phagocytes. Curr Protoc Immunol 2011;Chapter 14:Unit 14.26
19. Park D, Han CZ, Elliott MR, et al. Continued clearance of apoptotic cells critically depends on the phagocyte Ucp2 protein. Nature 2011;477:220-224
20. Krishnamoorthy S, Recchiuti A, Chiang N, et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci USA 2010;107:1660-1665
21. Lecube A, Pachón G, Petriz J, Hernández C, Simó R. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. PLoS ONE 2011;6:e23366
22. Ferracini M, Martins JO, Campos MR, Anger DB, Jancar S. Impaired phagocytosis by alveolar macrophages from diabetic rats is related to the deficient coupling of LTs to the Fc gamma R signaling cascade. Mol Immunol 2010;47:1974-1980
23. Khanna S, Biswas S, Shang Y, et al. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS ONE 2010;5: e9539
24. O'Brien BA, Huang Y, Geng X, Dutz JP, Finegood DT. Phagocytosis of apoptotic cells by macrophages from NOD mice is reduced. Diabetes 2002; 51:2481-2488
25. Leverrier Y, Okkenhaug K, Sawyer C, Bilancio A, Vanhaesebroeck B, Ridley AJ. Class I phosphoinositide 3-kinase p110beta is required for ap-optotic cell and Fcgamma receptor-mediated phagocytosis by macrophages. J Biol Chem 2003;278:38437-38442
26. Li S, Sun Y, Liang CP, et al. Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fish oil diet. Circ Res 2009;105:1072-1082
27. Norling LV, Dalli J, Flower RJ, Serhan CN, Perretti M. Resolvin d1 limits polymorphonuclear leukocyte recruitment to inflammatory Loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol 2012;32:1970-1978
28. Bae YS, Lee HY, Jo EJ, et al. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J Immunol 2004;173:607-614
29. Wetzler C, Kämpfer H, Stallmeyer B, Pfeilschifter J, Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol 2000;115: 245-253
30. Palmer CD, Mancuso CJ, Weiss JP, Serhan CN, Guinan EC, Levy O. 17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli. J Leukoc Biol 2011;90: 459-470
31. Liu BF, Miyata S, Kojima H, et al. Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes 1999;48:2074-2082
32. Jeffcoate WJ, Lipsky BA, Berendt AR, et al.; International Working Group on the Diabetic Foot. Unresolved issues in the management of ulcers of the foot in diabetes. Diabet Med 2008;25:1380-1389
33. Norling LV, Spite M, Yang R, Flower RJ, Perretti M, Serhan CN. Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol 2011;186:5543-5547
34. Titos E, Rius B, González-Périz A, et al. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol 2011;187:5408-5418
35. White PJ, Arita M, Taguchi R, Kang JX, Marette A. Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes 2010;59:3066-3073
36. Tian H, Lu Y, Shah SP, Hong S. 14S, 21R-dihydroxydocosahexaenoic acid remedies impaired healing and mesenchymal stem cell functions in diabetic wounds. J Biol Chem 2011;286:4443-4453
37. De Caterina R, Madonna R, Bertolotto A, Schmidt EB. n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. Diabetes Care 2007;30:1012-1026